Recruiting

Testing a new cancer drug alone and with standard therapy for ovarian cancer

Plain-English translation of NCT07278336 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Read our Ovarian Cancer research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This Phase 1 trial is testing a new investigational medication called to see if it is safe and effective for treating ovarian cancer. Researchers will test the medication alone in the first parts of the study, and then combined with (a standard ovarian cancer treatment) in later parts. About 219 people will participate at roughly 75 sites around the world over approximately 3 years.

Ovarian cancer is a serious disease, and many patients develop resistance to platinum-based chemotherapy or cannot tolerate it. This trial aims to find a new treatment option for people in these situations by testing whether this medication can slow or stop cancer growth.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or unresectable high-grade serous ovarian, fallopian tube, or primary peritoneal cancer confirmed by a tissue biopsy
your cancer is platinum-resistant (came back within 6 months of your last platinum chemotherapy) or you cannot receive platinum-based drugs
you have received appropriate standard cancer treatments and your doctor believes you are suitable for this early-stage study
you have had no more than 2 lines of previous cancer therapy since developing platinum resistance or ineligibility
you are an adult able to attend regular clinic visits and undergo medical assessments, blood tests, and scans

You likely don't qualify if…

you have a different type of ovarian cancer (such as endometrioid, low-grade, clear cell, mucinous, or borderline tumors)
you have previously received an antibody-drug conjugate containing a topoisomerase inhibitor
you have a history of interstitial lung disease or pneumonitis that required steroid treatment, or current signs of lung inflammation on a screening chest scan
you are currently taking strong medications that interact with the study drug within 14 days before starting treatment

What participation looks like

You will receive the medication as an intravenous infusion on a regular schedule at a hospital or clinic. Depending on which part of the study you join, you may receive increasing doses of the medication alone, a set dose alone, or the medication combined with . You will need to attend frequent clinic visits for medical check-ups, blood tests, and imaging scans throughout the approximately 3-year study to monitor how you respond and watch for side effects.

Testing a new cancer drug alone and with standard therapy for ovarian cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(17 sites)